Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
ORAP is an oral tablet approved in 1984 for an undisclosed indication. The specific mechanism of action and therapeutic class are not currently documented in available data.
Approaching loss of exclusivity with moderate competitive pressure (30%) suggests team focus is transitioning from growth maintenance to LOE mitigation strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®
Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients
Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients
A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects
Vorapaxar and Lower Extremity Bypass Grafts
Worked on ORAP at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ORAP currently shows zero linked job openings, reflecting its mature lifecycle stage and LOE-approaching status. Career opportunities are limited and likely focused on defensive commercial strategies rather than expansion.